ATE230020T1 - Katalytische antikörperkomponente - Google Patents

Katalytische antikörperkomponente

Info

Publication number
ATE230020T1
ATE230020T1 AT91907066T AT91907066T ATE230020T1 AT E230020 T1 ATE230020 T1 AT E230020T1 AT 91907066 T AT91907066 T AT 91907066T AT 91907066 T AT91907066 T AT 91907066T AT E230020 T1 ATE230020 T1 AT E230020T1
Authority
AT
Austria
Prior art keywords
catalytic
catalytic antibody
antibody components
disclosed
methods
Prior art date
Application number
AT91907066T
Other languages
English (en)
Inventor
Sudhir Paul
Michael J Powell
Richard J Massey
John H Kenten
Original Assignee
Igen Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igen Int Inc filed Critical Igen Int Inc
Application granted granted Critical
Publication of ATE230020T1 publication Critical patent/ATE230020T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
AT91907066T 1990-03-23 1991-03-22 Katalytische antikörperkomponente ATE230020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/498,225 US5229272A (en) 1989-04-25 1990-03-23 Catalytic antibody components
PCT/US1991/001948 WO1991014769A1 (en) 1990-03-23 1991-03-22 Catalytic antibody components

Publications (1)

Publication Number Publication Date
ATE230020T1 true ATE230020T1 (de) 2003-01-15

Family

ID=23980122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907066T ATE230020T1 (de) 1990-03-23 1991-03-22 Katalytische antikörperkomponente

Country Status (11)

Country Link
US (1) US5229272A (de)
EP (1) EP0521996B1 (de)
JP (1) JPH05508073A (de)
KR (1) KR100244677B1 (de)
AT (1) ATE230020T1 (de)
AU (1) AU643776B2 (de)
CA (1) CA2038911A1 (de)
DE (1) DE69133179T2 (de)
IL (1) IL97653A (de)
WO (1) WO1991014769A1 (de)
ZA (1) ZA912036B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
AU656181B2 (en) * 1991-05-03 1995-01-27 Pasteur Sanofi Diagnostics Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
US5302707A (en) * 1992-03-26 1994-04-12 Affymax Technologies N.V. 5-fluorouridine nucleoside phosphate compounds
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6852507B1 (en) * 1994-01-31 2005-02-08 L'institut National De La Recherche Agronomique Recombinant baculovirus and use thereof in the production of monoclonal antibodies
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
ES2283005T3 (es) * 1995-07-21 2007-10-16 University Of Nebraska Board Of Regents Composiciones y procedimientos para catalizar la hidrolisis de gp 120 de hiv.
US5801064A (en) * 1995-12-04 1998-09-01 Foresman; Mark D. Assay methods and reagents for detecting autoantibodies
US5993549A (en) * 1996-01-19 1999-11-30 Deutsche Forschungsanstalt Fuer Luft- Und Raumfahrt E.V. Powder coating apparatus
WO1997030089A1 (en) * 1996-02-13 1997-08-21 Regents Of The University Of California Novel antibody-cytokine fusion protein, and methods of making and using the same
EP1987845B1 (de) 1997-11-20 2012-03-21 Vical Incorporated Behandlung von Krebs mithilfe Cytokin-exprimierender Polynukleotide und Zusammensetzungen dafür
US20030044420A1 (en) * 1999-09-24 2003-03-06 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
US7084256B2 (en) * 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112014022692A8 (pt) 2012-03-14 2021-07-20 Regeneron Pharma molécula de ligação de antígeno multiespecífica
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4492751A (en) * 1978-04-10 1985-01-08 Miles Laboratories, Inc. Heterogenous specific binding assay employing an enzyme substrate as label
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4493890A (en) * 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU3745285A (en) * 1983-11-29 1985-06-13 Igen, Inc. Method of catalyzing chemical reactions
US5030717A (en) * 1986-09-17 1991-07-09 Scripps Clinic And Research Foundation Antibodies which catalyze hydrolysis of ester bonds
US4659567A (en) * 1984-09-07 1987-04-21 Scripps Clinic & Research Foundation Molecules with antibody combining sites that bind to hydrolytic transition states
WO1986006742A1 (en) * 1985-05-07 1986-11-20 California Biotechnology Inc. Fused proteine for enzyme immunoassay system
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US4792446A (en) * 1986-06-23 1988-12-20 Igen, Inc. Production of antibody catalysts
US4900674A (en) * 1987-05-28 1990-02-13 Scripps Clinic And Research Foundation Antibody combining sites that exhibit amide or ester synthase activity
ZA888978B (en) * 1987-12-04 1990-07-25 Du Pont Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
AU634186B2 (en) * 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
JPH04502708A (ja) * 1989-01-17 1992-05-21 スクリップス クリニック アンド リサーチ ファウンデーション 立体特異的触媒作用を示す抗体結合部位を有する分子
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction

Also Published As

Publication number Publication date
EP0521996B1 (de) 2002-12-18
AU7559291A (en) 1991-10-21
CA2038911A1 (en) 1991-09-24
IL97653A (en) 1998-01-04
EP0521996A1 (de) 1993-01-13
US5229272A (en) 1993-07-20
ZA912036B (en) 1991-12-24
KR100244677B1 (ko) 2000-02-15
IL97653A0 (en) 1992-06-21
EP0521996A4 (en) 1993-06-30
WO1991014769A1 (en) 1991-10-03
DE69133179D1 (de) 2003-01-30
DE69133179T2 (de) 2003-11-13
JPH05508073A (ja) 1993-11-18
AU643776B2 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
DE69133179T2 (de) Katalytische antikörperkomponente
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
NZ331299A (en) Antibody variants with reduced affinity for a cell-surface antigen
ES2116790T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
BR9809656A (pt) Composição imunopotencializante
PT856520E (pt) Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
NO163920C (no) Fremgangsmaate for bestemmelse av pivka-ii i fysiologiske proever.
ID20117A (id) Antibodi anti-fas
DE3850993T2 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
DK329789A (da) Monoklonalt antistof
ES2125011T3 (es) Procedimiento inmunologico de la antitrombina iii activada por un glicosaminoglicano, anticuerpos monoclonales correspondientes y su procedimiento de obtencion.
PT81050B (pt) Anticorpo monoclonal anti-urocinase e processo para a preparacao de composicoes de materia de teste biologicos que o utilizam
NO974793L (no) Fremgangsmåte til fremstilling av et monoklonalt antistoff mot Onkostatin M, eller et fragment derav
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
KR950031110A (ko) 인간 혈증 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주
FI956041A (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan
ECSP951605A (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora, case ran 4105/171

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0521996

Country of ref document: EP

REN Ceased due to non-payment of the annual fee